Status:

WITHDRAWN

A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris

Lead Sponsor:

Incyte Corporation

Conditions:

Pemphigus Vulgaris

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to assess the safety and tolerability of parsaclisib in participants with mild to moderate pemphigus vulgaris.

Eligibility Criteria

Inclusion

  • Clinically documented and confirmed diagnosis of pemphigus vulgaris: minimum of 6 months of pemphigus vulgaris diagnosis; positive for anti-desmoglein (DSG)1 or DSG3; Pemphigus Disease Area Index score of 8 to 45 points; active skin, scalp, or mucosal lesions.
  • Disease progression after treatment with standard therapies that are known to confer clinical benefit, or intolerant to treatment; there is no limit to the number of prior treatment regimens.
  • Willingness to avoid pregnancy or fathering children.
  • If required, willing to receive Pneumocystis jirovecii pneumonia prophylaxis during the study period.

Exclusion

  • Pregnant or breast-feeding female.
  • Participants with pemphigus vulgaris who are treatment-naive.
  • Use of protocol-specified medications within defined periods before baseline.
  • Evidence or history of clinically significant infection or protocol-defined medical conditions
  • Laboratory values outside the protocol-defined range at screening.
  • Known or suspected allergy to parsaclisib or any component of the study drug.
  • Known history of clinically significant drug or alcohol abuse in the last year before baseline.
  • Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator.
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Key Trial Info

Start Date :

March 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2020

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT03780166

Start Date

March 1 2019

End Date

November 1 2020

Last Update

September 13 2019

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris | DecenTrialz